Rapport Therapeutics (RAPP)

• Market cap: $415M
• 1 day: -1.47%
• 5 days: 18.67%
• 1 month: 11.35%
• 3 months: -20.25%
• 6 months: -55.99%
• Year to date: -38.12%
• 1 year: -45.29%
• 5 years: -45.29%
• 10 years: -45.29%
• Sector: Healthcare
• Industry: Biotechnology

About: Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Employees: 69

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

320% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 5

46% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 13

28% more funds holding

Funds holding: 54 [Q3] → 69 (+15) [Q4]

25% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]

22.42% more ownership

Funds ownership: 77.57% [Q3] → 99.99% (+22.42%) [Q4]

12% more capital invested

Capital invested by funds: $580M [Q3] → $649M (+$68.4M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $28 146% upside
• Avg. target: $28 146% upside
• High target: $28 146% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

JMP Securities Jason Butler 23% 1-year accuracy 9 / 40 met price target

146% upside $28

Market Outperform Initiated

8 Apr 2025